INCY News and Press, Incyte Corporation From 12/11/21

- Data from the CITADEL program of parsaclisib in patients with follicular, marginal zone and mantle cell lymphomas were accepted as oral presentations at the 63rd American Society of Hematology Annual Meeting and Exposition (ASH 2021) - Data supported Incyte’s New Drug...

Oncolytics Biotech (NASDAQ:ONCY) gains 9.2% premarket after announcing a positive interim safety update from phase 2 IRENE trial at the 2021 San Antonio Breast Cancer Symposium (SABCS). The IRENE trial is designed to evaluate the safety and efficacy of pelareorep in combination with...

FN Media Group Presents USA News Group News Commentary Vancouver, BC –December 8, 2021 – USA News Group –  Growing at a healthy CAGR of 14.1%, the Cancer Immunotherapy Market is being projected to hit nearly $310 billion by 2030, according to ...

VANCOUVER – USA News Group – Growing at a healthy CAGR of 14.1%, the Cancer Immunotherapy Market is being projected to hit nearly $310 billion by 2030, according to Allied Analytics . Over the past decade, cancer drug revenues increased 70%, according to a retrospect...

Although the Healthcare sector is having a positive year in absolute terms, that isn't the case in relative terms. Biotech stocks are having a difficult year, in spite of many of those trading at dirt-cheap valuations that don't even reflect the cash they have in-hand. It's very l...

Following a Drug Safety Communication (DSC) issued by the FDA after the review of the post-marketing study for Pfizer’s (NYSE:PFE) XELJANZ (tofacitinib) in rheumatoid arthritis (RA), AbbVie (NYSE:ABBV) has revised its U.S. label for its JAK inhibitor RINVOQ. The update, related to drug...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

Pfizer's vaccine sales have a huge impact in 2021, and that will also be the case next year. Pfizer's COVID antiviral could deliver revenue of up to $20 billion next year, likely making 2022 a great year for Pfizer. Even without current COVID tailwinds, Pfizer seems to be position...

This portfolio strategy uses the quarterly 13F filings to extract 50 consensus stocks from 40 large hedge funds that have more than $3.5 billion Assets Under Management. After the Q2-2021 13F filings, the consensus holdings were updated, 6 stocks were removed and 6 added from the univ...

Incyte Corporation runs a biopharmaceutical business with several commercialized products. The company does not only envisage that Jakafi may bring close to $3 billion in peak sales. Monjuvi is also expected to report $500-$750 million in sales. Notice that Pemazyre experienced 31...